2022 Announcements

CLINUVEL
Posted by CLINUVEL
November 17, 2022

Jefferies London Healthcare Conference

CLINUVEL's Chief Executive Officer, Dr Philippe Wolgen, presents to the Jefferies Healthcare...

Read More
CLINUVEL
Posted by CLINUVEL
November 9, 2022

CLINUVEL Communiqué V

News Communiqué V discusses CLINUVEL's strong financial results in the face of...

Read More
CLINUVEL
Posted by CLINUVEL
November 7, 2022

Appendix 3Y - Change of Director’s Interest Notice

Melbourne, Australia, 07 November 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
October 31, 2022

Appendix 4C & Activity Report

CLINUVEL PHARMACEUTICALS LTD today released its Appendix 4C – Quarterly Cashflow Report...

Read More
CLINUVEL
Posted by CLINUVEL
October 26, 2022

Chair's Address

Dear Shareholders, I have a few key points to make before we...

Read More
CLINUVEL
Posted by CLINUVEL
October 26, 2022

Results of Annual General Meeting 2022

In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations...

Read More
CLINUVEL
Posted by CLINUVEL
October 21, 2022

CLINUVEL Pharmaceuticals Investor Briefing Melbourne

CLINUVEL held an Investor Briefing in Melbourne, with a presentation by Managing...

Read More
CLINUVEL
Posted by CLINUVEL
October 20, 2022

First vitiligo patient enrolled in afamelanotide monotherapy study

CUV104 study to evaluate the role of afamelanotide as monotherapy in patients...

Read More
CLINUVEL
Posted by CLINUVEL
October 14, 2022

CLINUVEL's Sydney Soirée 2022

CLINUVEL's Sydney Soirée 2022 presentation

Read More
CLINUVEL
Posted by CLINUVEL
September 23, 2022
CLINUVEL
Posted by CLINUVEL
September 19, 2022

Strategic Update V

CLINUVEL today announced its fifth Strategic Update, focused on the evolution and...

Read More
CLINUVEL
Posted by CLINUVEL
September 13, 2022

H.C. Wainwright 24th Annual Global Investment Conference

CLINUVEL's Head of Investor Relations, Malcolm Bull, presents to the H.C. Wainwright...

Read More
CLINUVEL
Posted by CLINUVEL
September 8, 2022

CLINUVEL confirms AGM date

CLINUVEL confirms the date for the Company’s 2022 Annual General Meeting.

Read More
Lachlan Hay
Posted by Lachlan Hay
September 5, 2022

CLINUVEL submits SCENESSE® label expansion for adolescent EPP patients

European regulatory submission follows clinical support for SCENESSE® treatment in EPP patients...

Read More
CLINUVEL
Posted by CLINUVEL
September 2, 2022

CLINUVEL Kommuniqué IV

Seit dem letzten News Communiqué vom 23. Juni hat CLINUVEL die Entwicklung...

Read More